Bio-Rad Laboratories, Inc.
BIO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,567 | $2,671 | $2,802 | $2,923 |
| % Growth | -3.9% | -4.7% | -4.1% | – |
| Cost of Goods Sold | $1,188 | $1,244 | $1,235 | $1,284 |
| Gross Profit | $1,379 | $1,427 | $1,567 | $1,638 |
| % Margin | 53.7% | 53.4% | 55.9% | 56.1% |
| R&D Expenses | $296 | $247 | $257 | $261 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $814 | $842 | $828 | $877 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,110 | $1,089 | $1,085 | $1,138 |
| Operating Income | $269 | $338 | $483 | $500 |
| % Margin | 10.5% | 12.6% | 17.2% | 17.1% |
| Other Income/Exp. Net | -$2,612 | -$1,188 | -$5,187 | $4,949 |
| Pre-Tax Income | -$2,343 | -$850 | -$4,704 | $5,449 |
| Tax Expense | -$498 | -$213 | -$1,077 | $1,195 |
| Net Income | -$1,844 | -$637 | -$3,628 | $4,254 |
| % Margin | -71.9% | -23.9% | -129.5% | 145.6% |
| EPS | -65.36 | -21.82 | -121.79 | 142.61 |
| % Growth | -199.5% | 82.1% | -185.4% | – |
| EPS Diluted | -65.36 | -21.82 | -121.79 | 140.83 |
| Weighted Avg Shares Out | 28 | 29 | 30 | 30 |
| Weighted Avg Shares Out Dil | 28 | 29 | 30 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $82 | $101 | $58 | $19 |
| Interest Expense | $49 | $49 | $38 | $2 |
| Depreciation & Amortization | $152 | $146 | $177 | $138 |
| EBITDA | -$2,142 | -$655 | -$4,489 | $5,588 |
| % Margin | -83.5% | -24.5% | -160.2% | 191.2% |